PDCD1 and lung carcinoma: Immune checkpoint inhibitors (ICI), particularly programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors, are standard treatment options for several malignancies, including lung cancer (13–16).